The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
=== Cryo-EM Facility === The cryo-EM facility at the Life Sciences Institute offers a wide range of advanced microscopes and technologies for cryo-electron microscopy, cryo-electron tomography, and correlative light and electron microscopy (CLEM).
Despite his triumph in Rome, he lost his opening round match at the French Open. During the grass court season, Zverev made another singles final and again faced Federer at the Halle Open, but could not defeat him this time. He and his brother also finished runner-up in the doubles event to Łukasz Kubot and Marcelo Melo. At Wimbledon, he achieved his best result at a major event to date, ultimately losing in the fourth round to the previous year's runner-up Milos Raonic in a tight five-set match. Back on hard courts, Zverev won his last two titles of the season in August. He won the Washington Open as well as a second consecutive Masters title at the Canadian Open, only dropping a single set at each tournament in each of his opening matches. Notably, he needed to save three match points in his first match in Canada against Richard Gasquet, including a 49 shot rally. He then defeated Roger Federer in the final to become the first player outside of the Big Four to win multiple Masters titles in the same season since David Nalbandian in 2007. Despite this success, he was upset in the second round of the US Open by fellow Next Gen player Borna Ćorić. At the end of the season, Zverev qualified for both the inaugural Next Generation Finals as one of the top seven 21-and-under players, and the ATP Finals as one of the top eight players in the world. He opted to skip the former event to focus on the latter. At the ATP Finals, Zverev was grouped with Roger Federer, Marin Čilić, and Jack Sock.
Treatments are available to reduce the severity of some HD symptoms. For many of these treatments, evidence to confirm their effectiveness in treating symptoms of HD specifically are incomplete. As the disease progresses, the ability to care for oneself declines, and carefully managed multidisciplinary caregiving becomes increasingly necessary. Although relatively few studies of exercises and therapies have shown to be helpful to rehabilitate cognitive symptoms of HD, some evidence shows the usefulness of physical therapy, occupational therapy, and speech therapy.
== Pathophysiology == Cerebrospinal fluid is produced by the choroid plexus in the ventricles of the brain and contained by the dura and arachnoid layers of the meninges. The brain floats in CSF, which also transports nutrients to the brain and spinal cord. As holes form in the spinal dura mater, CSF leaks out into the surrounding space. The CSF is then absorbed into the spinal epidural venous plexus or soft tissues around the spine. Due to the sterile conditions of the soft tissues around the spine, there is no risk of meningitis.
Sources: en.wikipedia.org
=== eRF3 binding === The binding of eRF3 and GTP to eRF1 to form a complex is essential for termination of translation. The interaction between the C domains of both eRF1 and eRF3 is the major force holding the complex together. However, it was later discovered that the M domain also contributes to the stability of the complex. The positioning of eRF3 near the GGQ motif, which is in the C domain, allows greater catalytic effects of eRF1 hydrolyzing the peptidyl-tRNA.
The visualization of single molecules, single biological cells, biological tissues and nanomaterials is very important and attractive approach in analytical science. Also, hybridization with other traditional analytical tools is revolutionizing analytical science. Microscopy can be categorized into three different fields: optical microscopy, electron microscopy, and scanning probe microscopy. Recently, this field has been rapidly progressing because of the rapid development of the computer and camera industries.
In the Old Testament, Jethro was Moses' father-in-law, a Kenite shepherd and priest of Midian, sometimes called Reuel (or Raguel). In Exodus, Moses' father-in-law is initially referred to as "Reuel" (Exodus 2:18) but afterwards as "Jethro" (Exodus 3:1). He was also identified as the father of Hobab in Numbers 10:29, though Judges 4:11 identifies him as Hobab. Muslim scholars and the Druze identify Jethro with the prophet Shuayb, also said to come from Midian. For the Druze, Shuayb is considered the most important prophet, and the ancestor of all Druze. They believe he was a "hidden" and "true prophet" who communicated directly with God and then passed on that knowledge to Moses, whom they describe as a "recognised" and "revealed prophet". According to Druze belief, Moses was allowed to wed Zipporah, the daughter of Jethro, after helping save his daughters and their flock from competing herdsmen. Nabi Shuʿayb is the site recognized by Druze as the tomb of Shuʿayb. It is located at Hittin in the Lower Galilee and is the holiest shrine and most important pilgrimage site for the Druze.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.